Table 2.
Frequency, Hz | Peak Amplitude, pA | |
---|---|---|
A. Muscarinic Receptors | ||
Baseline (4) | 1.27 ± 0.17 | 14.61 ± 2.62 |
Atropine | 1.072 ± 0.23 | 14.74 ± 2.47 |
Atropine + carbachol | 1.19 ± 0.33 | 14.51 ± 0.85 |
Baseline (5) | 0.54 ± 0.14 | 13.85 ± 1.22 |
Atropine | 0.46 ± 0.17 | 13.62 ± 1.62 |
Atropine + paraoxon | 0.55 ± 0.20 | 14.79 ± 1.44 |
Baseline (4) | 0.91 ± 0.14 | 13.70 ± 2.21 |
Carbachol | 1.49 ± 0.43* | 17.76 ± 1.69 |
Carbachol + atropine | 1.15 ± 0.48 | 15.45 ± 1.08 |
Baseline (4) | 1.18 ± 0.32 | 13.77 ± 1.60 |
Paraoxon | 1.84 ± 0.60* | 15.01 ± 2.03* |
Paraoxon + atropine | 1.21 ± 0.36 | 14.69 ± 1.57 |
B. Nicotinic receptors | ||
Baseline (5) | 1.01 ± 0.34 | 18.63 ± 1.93 |
α-bungarotoxin | 1.17 ± 0.22 | 15.65 ± 3.08 |
α-bungarotoxin + nicotine | 1.28 ± 0.32 | 15.68 ± 2.84 |
Baseline (4) | 1.21 ± 0.16 | 12.049 ± 0.09 |
α-bungarotoxin | 1.31 ± 0.18 | 12.04 ± 0.10 |
α-bungarotoxin + paraoxon | 1.69 ± 0.15* | 11.88 ± 0.10 |
Baseline (n = 5) | 1.49 ± 0.38 | 14.59 ± 2.74 |
Nicotine | 1.73 ± 0.42* | 15.55 ± 2.76* |
Nicotine + α-bungarotoxin | 1.51 ± 0.45 | 14.75 ± 1.74 |
Baseline (4) | 1.59 ± 0.19 | 11.31 ± 0.09 |
Paraoxon | 2.36 ± 0.33** | 12.08 ± 0.27* |
Paraoxon + α-bungarotoxin | 2.28 ± 0.30* | 12.24 ± 0.42* |
The impact of the cholinergic agonists paraoxon, carbachol, and nicotine coapplied with antagonists before and after application of antagonists of muscarinic or nicotinic receptors on sEPSXC frequency and amplitude.
P < 0.05;
P < 0.005 using repeated measures ANOVA test.